LYG2 Inhibitors
Chemical inhibitors of LYG2 can effectively interfere with its function by targeting various aspects of the glycosylation process. Allopurinol, for example, inhibits xanthine oxidase, an enzyme implicated in purine metabolism, which may interact with LYG2. The inhibition of xanthine oxidase by Allopurinol leads to a reduction in uric acid and other metabolites, potentially limiting the substrates necessary for LYG2 activity. Similarly, Methotrexate acts on the folate pathway by inhibiting dihydrofolate reductase. The resulting accumulation of dihydrofolate can indirectly affect LYG2's associated glycan processing by disrupting the glycosylation process. Swainsonine and Castanospermine, on the other hand, inhibit mannosidase II and glucosidase, respectively. These enzymes are crucial for the correct folding and processing of glycoproteins, and their inhibition can result in misfolded glycoproteins or incorrect glycan structures, thereby impeding LYG2's role in glycoprotein maturation.
Furthermore, the function of LYG2 can be compromised by chemicals such as Kifunensine, which inhibits mannosidase I leading to the buildup of high-mannose glycoproteins that may not be properly processed for LYG2 activity. Deoxynojirimycin and Deoxymannojirimycin both inhibit different glucosidases, essential for the folding and processing of N-linked glycoproteins, resulting in an accumulation of incorrectly folded proteins that require LYG2 for their maturation. Fumagillin's inhibition of methionine aminopeptidase-2 can also indirectly affect LYG2 by altering protein synthesis and maturation. Brefeldin A and Monensin disrupt the function of the Golgi apparatus, a central hub for protein sorting and glycosylation. By inhibiting Golgi function, these chemicals prevent the proper modification and sorting of glycoproteins, thus functionally inhibiting LYG2. Lastly, Endoglycosidase H cleaves certain oligosaccharides from N-linked glycoproteins, which can interfere with the normal processing of N-linked glycans, impacting LYG2's role in the glycosylation pathway. Tunicamycin disrupts the initial steps of glycoprotein synthesis by blocking N-linked glycosylation, directly affecting the pathway in which LYG2 is involved, leading to its functional inhibition.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Allopurinol inhibits xanthine oxidase, an enzyme that LYG2 may interact with during purine metabolism. Inhibition of xanthine oxidase by Allopurinol can lead to reduced production of uric acid and other metabolites, potentially decreasing the availability of substrates required for LYG2 function. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate targets dihydrofolate reductase, which is involved in the folate pathway. LYG2, being associated with glycan processing, could be functionally inhibited by the accumulation of dihydrofolate, as a result of Methotrexate activity, thus affecting the glycosylation process where LYG2 is implicated. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, which could lead to an accumulation of misfolded glycoproteins. This could inhibit LYG2 by disrupting the glycoprotein processing and transport pathways where LYG2 is involved, leading to functional inhibition due to the accumulation of incorrect glycan structures. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine is an inhibitor of glucosidase, which can disrupt the proper folding of N-linked glycoproteins. This could inhibit LYG2 by impairing the proper assembly or processing of glycoproteins that require LYG2 function, directly impeding its role in the glycosylation pathway. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine acts as a mannosidase I inhibitor, which could result in the accumulation of high-mannose glycoproteins. LYG2, which may function in later stages of glycoprotein processing, could be inhibited as the high-mannose glycoproteins may not be properly processed, indirectly leading to a functional inhibition of LYG2. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
Deoxynojirimycin inhibits glucosidase enzymes, which are important for the proper folding and processing of N-linked glycoproteins. This inhibition can interrupt the glycan processing pathway that requires LYG2 function, leading to a functional inhibition of LYG2 due to the accumulation of improperly folded glycoproteins. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin is a competitive inhibitor of mannosidase I, which participates in the processing of N-linked glycans. By inhibiting mannosidase I, this chemical can cause a build-up of glycoproteins that are not fully processed, thereby inhibiting the function of LYG2 in glycoprotein maturation. | ||||||
Fumagillin | 23110-15-8 | sc-200377 sc-200377A sc-200377B sc-200377C sc-200377D | 1 mg 5 mg 25 mg 100 mg 500 mg | $104.00 $393.00 $541.00 $1363.00 $5212.00 | 1 | |
Fumagillin inhibits methionine aminopeptidase-2, which could affect protein synthesis and maturation. This could lead to a functional inhibition of LYG2 as it may rely on the maturation of proteins that are substrates or regulators of its glycosylation activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the function of the Golgi apparatus, essential for protein sorting and glycosylation. By inhibiting the Golgi function, Brefeldin A can functionally inhibit LYG2 by preventing the proper sorting and modification of glycoproteins that LYG2 is likely to process. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation by inhibiting dolichyl phosphate N-acetylglucosamine phosphotransferase. This can functionally inhibit LYG2 by halting the initial steps of glycoprotein synthesis, directly affecting the pathway in which LYG2 operates. | ||||||